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Mitral Valve Therapies
Lessons Learned and Future Directions*Anelechi C. Anyanwu, MD, David H. Adams, MDI n this issue of the Journal, the EVEREST II (Endo-vascular Valve Edge-to-Edge REpair Study II) in-vestigators have reported the 5-year results of
their randomized trial comparing percutaneous
edge-to-edge mitral valve repair, using the MitraClip
device (Abbott, Menlo Park, California), with mitral
valve surgery (1). The primary outcomes of the trialSEE PAGE 2844have been previously published (2). We congratulate
the investigators for concluding an important pivotal
study in the emerging ﬁeld of transcatheter mitral
valve therapy and for providing key information on
percutaneous edge-to-edge mitral repair. We
have already learned 4 principal lessons from the
EVEREST II trial: 1) the clip procedure is safe; 2) the
clip may be applied to both degenerative and func-
tional subtypes (although with less efﬁcacy in
reducing mitral valve regurgitation compared with
surgery); 3) patients may safely undergo surgical rein-
tervention if the clip fails; and 4) improvements in
symptoms occur after successful clip treatment. The
U.S. Food and Drug Administration (FDA) has now
approved the device for use in the United States for
patients with signiﬁcant symptomatic degenerative
mitral regurgitation (MR) who are too high risk for
surgery. The role of clip therapy in functional MR*Editorials published in the Journal of the American College of Cardiology
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vant to the contents of this paper to disclose.has not been established and is the subject of an
ongoing U.S. trial (3), but the device is widely used
in Europe for this indication (4).
The current report provides new data on the
midterm performance of the clip in the EVEREST II
study.Device failure andneed for surgical intervention
were uncommon after the ﬁrst year post-clip implant,
and importantly, midterm mitral stenosis occurred
in <1% of implants. Clip repairs did have a higher
midterm incidence of reoperation and recurrence of
moderate or severe regurgitation compared with sur-
gery; however, patient survival was the same (1).
The EVEREST II trial was pioneering and, despite
concerns regarding the trial design and conduct (5),
the experience and observations from this study
provide future investigators with a framework on
which to conduct trials of transcatheter mitral valve
therapy (Table 1). We have previously discussed the
unique features that will set apart trials of trans-
catheter mitral valve replacement (TMVR) from those
of transcatheter aortic valve replacement (6). The
EVEREST II study demonstrates that trials of percu-
taneous mitral valve repair pose even greater chal-
lenges. Several lessons gleaned from the EVEREST II
study can help form the framework for future trials of
transcatheter mitral valve therapy.
STUDY POPULATIONS
A major limitation of EVEREST II was the inclusion of
both degenerative MR (for which the role of surgery is
certain) and functional MR (where the role of surgery
and transcatheter intervention remain uncertain).
This greatly limited interpretation and applicability
of the results. The trial was unable to draw conclu-
sions regarding the role of the clip in either func-
tional or degenerative etiology, because neither was
speciﬁcally studied. Even within the degenerative
TABLE 1 Key Elements for Future Trials of Percutaneous
Mitral Valve Repair
1. Study populations should not be heterogeneous.
2. Inclusion criteria should mirror current guidelines and practice.
3. High-quality repair centers are critical.
4. Maintaining patient compliance should be a major focus.
5. Young and low-risk patients should be excluded from trials of
irreversible devices.
6. Endpoints should be clinically relevant.
7. Inclusion criteria should mandate planned surgical repair of the
valve.
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that have different implications for valve repairability
(7). Although there is an obvious attraction to study
all-comers, doing so risks the same predicament of
EVEREST II, as it can be impossible to draw reliable
conclusions about relevant clinical subsets. To
demonstrate effectiveness of a percutaneous mitral
therapy, study of a well-deﬁned etiology (such as
degenerative) and lesion subset (such as P2 prolapse
due to chordal rupture) will likely yield results that
are more deﬁnitive.
INCLUSION CRITERIA
To allow generalizability of results, inclusion criteria
should closely mirror current practice and agreed in-
dications for intervention. In EVEREST II, the inclu-
sion criteria included asymptomatic or symptomatic
patients with moderate to severe (3þ) regurgitation
(8), whereas current and previous guidelines recom-
mend mitral valve surgery for only patients with se-
vere (4þ) regurgitation (9–11). Only 24% of patients in
EVEREST II had severe MR, as deﬁned by their core
laboratory assessment (2). The majority (71%) had
moderate to severe regurgitation—some of these pa-
tients, particularly those without symptoms, may not
meet agreed criteria for intervention in current prac-
tice. Indeed, although indication for surgery was a pre-
requisite for trial entry, about one-third (13 of 41) of
patients who had a failed attempt at device placement
did not undergo subsequent surgical operation during
the initial study period (5), raising the question as to
how strong an indication for surgery had existed in
those patients in the ﬁrst place. It therefore becomes
difﬁcult to extrapolate the EVEREST II results, as there
is the possibility that the clip was used on less-severe
stages of disease. Of note, 5% of patients in the study
had mild or moderate MR, and should not have met
criteria for study inclusion; this highlights the impor-
tance of core laboratory adjudication of echocardio-
graphic images before recruitment of patients into
trials.QUALITY OF CENTERS
Although the paper did not provide a breakdown of
volume and outcomes among trial centers (1), this
was a likely variable. The mean number of clip
procedures per center was 5 and the mean number
of surgical procedures was 2.5. Most probably there
was considerable variation with relatively few high
enrollers and others as low enrollers. Procedural
outcomes may be linked to experience with the
new technology and with previous experience, such
that low enrollers may remain in early stages of the
learning curve for an entire study. Additionally, a
high enroller with suboptimal techniques and out-
comes could negatively inﬂuence measured effec-
tiveness of a new device. Although it is desirable to
include many centers to allow quick enrollment in a
trial, a more restricted number of participating
centers with balanced recruitment volume and
procedural quality will likely give a more robust
assessment of effectiveness of a novel device, albeit
at the expense of a longer recruitment period. It
may be argued that including more centers presents
a pragmatic real-world experience, but it should be
remembered that the role of trials of new devices
is not to determine how they perform in the real
world, but to determine whether they are safe
and effective when used in a proscribed and ideal
manner.
To test the effectiveness of percutaneous versus
surgical repair, trialists should choose surgical
centers on the basis of expertise in mitral valve
repair, rather than expertise in mitral valve surgery
(which includes also valve replacement), as the
skills for replacement and repair are not inter-
changeable. The EVEREST II investigators do not
report whether speciﬁc surgical expertise or volume
in mitral valve repair was a prerequisite for the 37
participating centers (2,8). Public information from
the FDA in their executive summary of EVEREST II,
however, indicated that a high proportion of pa-
tients with adverse events in the surgical arm were
operated on by surgeons who performed <15 mitral
valve repairs per year (5). Utilizing low-volume
mitral valve repair surgeons to perform trial pro-
cedures may not allow measurement of the true
effectiveness and safety of surgery. Of note, the
surgical arm of the EVEREST II trial had a 14%
valve replacement rate, and the only signiﬁcant
predictor for valve replacement in the surgical
cohort was the presence of bileaﬂet prolapse, which
was present in 47% of the replaced valves (12).
In experienced repair centers, bileaﬂet prolapse
should not be a strong predictor for replacement, as
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such valves at a rate exceeding 95% (13–16). In
addition, bleeding, which was the main complica-
tion in the primary safety composite outcome (2),
was weighted toward low-volume centers (5). All
these suggest that center volume and experience
could have confounded the results of EVEREST II.
For future trials, surgical center selection should be
on the basis of the ability to deliver guideline-
recommended therapy for the mitral disease being
studied at a rate pre-speciﬁed by investigators. At a
minimum, the researchers should disclose the full
dataset, including enrollment volumes and key
variations per site.
PATIENT COMPLIANCE
Maintaining consent in trials of percutaneous devices
versus surgery can be difﬁcult, as the EVEREST II trial
demonstrates. Compared with 3% in the clip arm,
16% of those randomized to surgery withdrew from
the study after randomization (2). Although these
patients were included in an intention-to-treat anal-
ysis (2), in reality they cannot be seen as a reﬂection
of the effectiveness of a procedure (but rather the
effectiveness of a strategy). From the device
perspective, what is most important is the effective-
ness of the procedure in patients who actually
received the procedure, or in whom it was attempted.
In effectiveness or safety trials comparing percuta-
neous valve therapy to surgery, the results of all
analyses (intention to treat, as treated, per protocol,
and so on) should be presented to fully evaluate the
trial.
Late follow-up also was an issue in EVEREST II.
The 12-month completeness of follow-up was 94%,
whereas at 5 years it was 87% in the clip group and
70% in the surgical group (1). The higher late follow-
up rates in the clip group could be indicative of bias
in perception by patients or bias in follow-up by
recruiting centers. Such biased follow-up could have
bearing on study outcomes (better follow-up could
translate into superior medical management and
surveillance, for example). Trial design should take
into account these considerations. Preferably, the
source of patients for entry should be patients who
have already accepted surgical treatment (and are
then introduced to a concept of a trial of a less-
invasive approach), as opposed to patients with a
disease who are primarily seeking the least invasive
therapy. Randomization after anesthetic induction is
one strategy that can circumvent withdrawals after
randomization.INCLUSION OF YOUNG AND
LOW-RISK PATIENTS
Early technical failures are inevitable with any
percutaneous (or surgical) repair. As failures will
generally necessitate surgical intervention, the fre-
quency of failures and the outcomes of patients with
failed techniques or devices is particularly relevant.
In EVEREST II, 21% of patients who were randomized
to a clip subsequently underwent surgical operation
within the ﬁrst year because of residual regurgitation
(12). Of these patients, 46% had the valve replaced,
and 54% were repaired (12). The overall valve
replacement rate in the ﬁrst year for patients who
received the clip was 10%. Therefore, a young
asymptomatic patient with mitral valve prolapse un-
dergoing clip placement could have up to a 10%
probability of ending up with a valve replacement.
In contrast, the same patient having surgery in a
reference center should expect a valve replacement
rate below 1% (13).
The key factor driving replacements (as opposed to
repair) after failed percutaneous clip repair appears to
have been leaﬂet injury by the clip (5,12). Therefore,
the possibility of permanent injury to the valve
should be considered when selecting patients for tri-
als of repair devices. If devices have an effect on the
valve that is irreversible, or only partially reversible,
then testing should be avoided in young and asymp-
tomatic patients (as surgical valve replacement is
particularly undesirable and negatively impacts life-
expectancy). Such devices should preferably be
tested on patients at high surgical risk, patients in
whom valve replacement would not be an unreason-
able option (such as rheumatic or functional etiology),
or patients in whom the consequences of valve
replacement may be less pronounced (such as older
patients). All TMVR devices, by deﬁnition, would also
fall into the category of devices with an irreversible
effect on the valve. Devices under development for
investigation and use on low-risk patients should not
permanently damage the valve in a way that could
compromise subsequent surgical repair.
ENDPOINTS
The essence of mitral valve intervention is resolution
of MR. All patient beneﬁts stem directly from this
effect. In primary MR, “the disease” is MR (11), and its
elimination should be the primary effectiveness
endpoint. However, its elimination in secondary MR,
although necessary, is not sufﬁcient to evaluate the
clinical utility of surgical or transcatheter mitral valve
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secondary MR should be chosen to demonstrate
clinical improvement.
The EVEREST II investigators used a composite
primary endpoint of death, freedom from surgery for
mitral valve dysfunction, and freedom from grade 3þ
or 4þ MR (73% in the surgery group vs. 55% in clip
group) (2). This primary endpoint was controversial
and was challenged by the FDA, which believed
freedom from 2þ (moderate) or greater regurgitation
was a more appropriate measure (5). Indeed, a post-
hoc analysis of EVEREST II data with freedom from
more than 2þ (rather than 3þ) regurgitation as the
main driver of the composite endpoint in a modiﬁed
intention-to-treat population found that only 31% of
clip patients would have met the more stringent pri-
mary endpoint, compared with 77% of surgical pa-
tients (5). Future trials should provide similar
sensitivity analyses to test key assumptions around
primary endpoints, so readers can attain a complete
picture of the data.
It is also problematic to have death as part of an
effectiveness endpoint for mitral repair devices, as
mitral valve repair is not typically performed to
enhance short-term survival. In a strict sense, death
should be part of a safety endpoint, as should other
major adverse major clinical events. Composite safety
endpoints should generally include death, major
adverse cardiac and cerebrovascular events, major
infective complications, major vascular complica-
tions, major organ dysfunction, major bleeding epi-
sodes, and other events speciﬁc to the procedures or
mitral disease being studied.
The inclusion of 2 units (U) or more blood trans-
fusion as part of the primary safety composite
endpoint in EVEREST II heavily skewed the safety
outcomes in favor of the clip (15% adverse events
with clip vs. 48% with surgery). If blood transfusion
(which was present in 45% of those who had surgery)
is excluded, the adverse event rates were 5% for the
clip and 10% for surgery (2). A major driver for blood
use in the surgical arm was the addition of concurrent
procedures (such as coronary bypass, maze, or other
valve surgery) in almost one-half the surgical
patients—considering that no clip patients received
concomitant procedures, this adds another unmea-
surable source of bias to the study (5). Ideally, the 2
arms of a percutaneous versus surgery trial should
differ only in the mode of delivery of valve therapy,
and not also in concomitant application of other
procedures. Where bleeding is used as part of a
safety endpoint, investigators should consider the
approach proposed by the Mitral Valve Academic
Research Consortium (MVARC) (17), which requiresthe presence of overt bleeding and also considers
drop in hemoglobin and clinical sequelae of bleeding,
rather than transfusion alone, to classify bleeding as
an adverse event. MVARC deﬁnes criteria for minor,
major, extensive, life-threatening, and fatal bleeding
events, and on the basis of MVARC classiﬁcation, 2 U
of blood transfusion (used in the EVEREST II as part
of the safety endpoint) would constitute a minor
bleeding event, 3 U transfusion would be major, and
4 U transfusion (or a hemoglobin drop of 4 g/l in 24 h)
would be extensive bleeding. Bleeding into critical
organ space (such as causing cardiac tamponade or
cerebral effects) would be life-threatening, regardless
of whether blood was transfused. The bleeding
endpoint chosen should be relevant for the procedure
being studied—for surgical procedures where minor
blood loss is obligatory, minor bleeding should not
constitute a safety endpoint (but extensive bleeding
should), whereas for a trial of 2 percutaneous
approaches, even a minor bleed may be deemed
relevant.
Finally, investigators should resist the temptation
to evaluate device effectiveness on the basis of 1-year
follow-up alone. We have learned more about the clip
therapy from this 5-year report that would not have
been known if the study closed after the 12-month
primary report. Other investigators should follow
the model of EVEREST II and maintain follow-up for
at least 5 years after study closure, as this midterm
information is critical for durability evaluation.
INCLUSION CRITERIA
The EVEREST II investigators speciﬁed the key study
inclusion criterion as patients who are candidates for
mitral valve repair or replacement. The clip, how-
ever, is a mitral valve repair device and should be an
alternative to surgical repair and not surgical
replacement. Thus, the results are confounded
because: 1) allowing valve replacement candidates
resulted in a lower frequency of surgical repair both
directly (by allowing surgeons a priori to decide pre-
operatively that a patient would have a replacement)
and indirectly (by permitting surgeons to convert
intraoperatively to replacement without impact on
study endpoints); and 2) percutaneous repair will
likely be less efﬁcacious in those patients whom a
surgeon has decided a priori would have a valve
replacement (if undergoing surgery). In surgical arms
of repair device trials, a surgical valve replacement
should be seen as a failure to meet an effectiveness
endpoint in the same way that a valve replacement
after a failed percutaneous device is deemed a thera-
peutic failure. In EVEREST II, the 14% in the surgical
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deemed surgical failures to make a fair comparison
with percutaneous repair. Future trials of percuta-
neous or surgical repair devices should pre-specify
surgical repairability as an inclusion criteria, and any
valve replacement (surgical or percutaneous) should
be seen as a failure.
We applaud the EVEREST II investigators for pio-
neering a new ﬁeld of investigation and therapy in
mitral valve regurgitation. The lessons we havelearned from this trial will allow us to better conduct
and understand trials on newer percutaneous repair
devices, which will likely emerge over the next
decade.
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